Open AccessFatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment
Author(s) -
Krishna Pandey,
Dharmendra Singh,
Chandra Shekhar Lal,
Vidya Nand Rabi Das,
Pradeep Das
Publication year - 2013
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/0022-3859.123161
Subject(s) - miltefosine , medicine , visceral leishmaniasis , acute pancreatitis , leishmaniasis , pancreatitis , intensive care medicine , dermatology , immunology
Pancreatitis is a known side effect of the once commonly used drug, sodium stibogluconate, for treatment of visceral leishmaniasis (VL). In India, miltefosine has recently been introduced as the first-line drug. Its side effects include loose motions, vomiting, and teratogenicity. We report here a case of a 41-year-old parasitologically confirmed male case of VL, who developed acute pancreatitis during treatment with miltefosine. On the 13 th day of treatment, he presented with abdominal pain and vomiting. The biochemical, hematological, and radiological features were suggestive of acute pancreatitis. The patient was put on conservative treatment for pancreatitis at the specialized center but succumbed to renal failure and septicaemia.